Formycon stock surges after settlement with Regeneron on Eylea biosimilar
PositiveFinancial Markets

Formycon's stock has seen a significant surge following a settlement with Regeneron regarding their Eylea biosimilar. This development is crucial as it not only boosts investor confidence but also positions Formycon favorably in the competitive biotech market. The agreement may pave the way for increased market access and revenue potential, highlighting the importance of strategic partnerships in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System